Clinical Trial Update: Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A completed randomized Phase III trial comparing docetaxel plus epirubicine versus docetaxel plus capecitabine in metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• DOCETAXEL (DOCETAXEL)
• Epirubicine (epirubicin)

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED